ArticleHemaSphere2022

Efficacy and Safety of the Combination of Tirabrutinib and Entospletinib With or Without Obinutuzumab in Relapsed Chronic Lymphocytic Leukemia.

Nadine Kutsch et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.